CClinicalTrials.gg
Status unknownNCT04652427Updated Dec 3, 2020

Application of Dexmedetomidine Hydrochloride Injection in Anesthesia for Patients Without Tracheal Intubation

An interventional study of Dexmedetomidine Hydrochloride 0.1 MG/ML and 0.9% Sodium Chloride Injection in Sedation Complication, sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

With 0.9% sodium chloride injection as a placebo control, to evaluate the effectiveness and safety of dexmedetomidine hydrochloride injection for sedation in patients with non-tracheal intubation

Read the detailed description

Clinically common non-systemic anesthesia mainly includes surface anesthesia, local immersion anesthesia, nerve block, regional blocking, intravertebral anesthesia. Patients under non-general anesthesia surgery, is still in a more sober state, easily due to external factors and increase the psychological and mental burden, even if the ideal anaesthetic effect can be achieved, but for autonomic nerve activities can not be completely and effectively eliminated. Hydrochloric acid right-metomidine is an alpha2-adrenaline receptor agonisant developed by Orion Pharma (Finland) and Abott (Usa) in collaboration. Unlike other sedative hypnotic sedatives, hydrochloric acid right metamine produces a sedative hypnotic effect by acting on the blue spot nuclear alpha2 receptor and the inflammatory endogenous sleep-stimulating pathway, allowing the patient to maintain a natural sleep state of non-fast eye III, which is characterized by the patient being stimulated or speech-altered, and does not produce respiratory inhibition during sedative hypnosis. In addition to the sedative effect, the right metomisurein also has anti-anxiety, reduce stress response, stable hemodynamics, analgesic, inhibitsalival secretion, anti-cold and diuretic function, and other sedative analgesic drugs when used with good synergy, can significantly reduce the use of other sedative analgesic drugs.

02

Conditions studied

  • Sedation Complication

Keywords

  • effectiveness
  • security
  • Dexmedetomidine Hydrochloride
  • Non-tracheal intubation anesthetic
03

In context

Lead sponsor

Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    1. 18\~65 years old (including 18 and 65 years old), no gender limit;
    1. 18 kg/m2 ≤BMI≤30 kg/m2;
    1. For patients undergoing elective surgery under non-general anesthesia, the expected duration of surgery is ≥30min;
    1. ASA classification is Ⅰ~Ⅲ;
    1. After the patient has a full understanding of the purpose and significance of this trial, he/she voluntarily participates in this clinical trial, agrees to contraception during the study period and within 3 days after the study medication, and signs an informed consent Intent.

Exclusion criteria

Exclusion Criteria:

    1. Patients who have received anesthesia or surgery within 7 days before randomization;
    1. Patients with a history of acute myocardial infarction or unstable angina within 6 months before the screening period;
    1. Bradycardia (heart rate \<50 beats/min), Ⅱ or Ⅲ degree atrioventricular block (not including Patients with pacemakers) and other severe arrhythmia and heart failure;
    1. Hypertension patients who are not satisfactorily controlled (systolic blood pressure ≥160 mmHg, and/or diastolic blood pressure ≥100 mmHg), or patients with hypotension (systolic blood pressure \<90 mmHg);
    1. People with mental system diseases (such as schizophrenia, depression, etc.) or cognitive impairment; Those with a history of epilepsy;
    1. Those who suffer from bronchial asthma or other severe respiratory diseases;
    1. Abnormal blood coagulation function (PT prolongation exceeds the upper limit of normal for 3 seconds and/or APTT prolongation exceeds. The upper limit of the normal value is 10 seconds);
    1. Abnormal liver and kidney function (ALT and/or AST>2 times the upper limit of normal, total bilirubin>1.5 Times the upper limit of normal, blood creatinine>1.5 times the upper limit of normal);
    1. Those who have used α2 adrenergic receptor agonists or antagonists within 14 days before randomization;
    1. Those who have used sedatives such as benzodiazepines and barbiturates within 7 days before randomization;
    1. People with a history of drug abuse, drug abuse and alcohol abuse, among which alcohol abuse is defined as the average daily drinking Liquor exceeds 2 units of alcohol (1 unit = 360 ml of beer or 45 ml of alcohol is 40% white wine or 150 ml wine);
    1. Those who are allergic to dexmedetomidine, midazolam, fentanyl and other pharmaceutical ingredients or components;
    1. Women who are pregnant or breastfeeding;
    1. Those who have participated in other clinical trials within 3 months before randomization;
    1. The researcher believes that there are any other circumstances that are not suitable for selection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Use Dexmedetomidine Hydrochloride to maintain a sedative

    Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.

    Drug: Dexmedetomidine Hydrochloride 0.1 MG/ML

  • Placebo comparator
    Sedative were maintained with a 0.9% sodium chloride injection

    Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.

    Drug: 0.9% Sodium Chloride Injection

Interventions

  • DrugDexmedetomidine Hydrochloride 0.1 MG/ML

    At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.

    Also known as: sedation

  • Drug0.9% Sodium Chloride Injection

    At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.

    Also known as: saline solution

06

What researchers measure

Primary outcomes

  1. Changes in the OAA/S score of the subject during the study medication.

    At least 15 minutes before anesthesia, the study drug was given sedation according to the dosing schedule. At the end of the loading dose of the study drug, an alertness/sedation score (OAA/S) was performed, and then it entered the maintenance dosing phase, which was performed every 5 minutes until the end of the operation OAA/S score. OAA/S≤4 means that the required level of sedation has been reached, and anesthesia can be performed after starting the study drug for ≥15 minutes and reaching the required level of sedation. During the administration of the study drug, OAA/S ≤4 should always be maintained.

    Time frame: 15min after giving the drug, every five minutes during anesthesia

07

Study locations

1 of 1 sites recruiting
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
    Recruiting
08

References and documents

Publications

  • Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010 Jan 1;110(1):47-56. doi: 10.1213/ane.0b013e3181ae0856. Epub 2009 Aug 27. PubMed 19713256 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04652427
Lead sponsor
Peking University People's Hospital
Responsible party
Yi Feng, MD (Director of department of anesthesiology and pain management, Peking University People's Hospital) — Principal investigator
First posted
Dec 3, 2020
Start date
Aug 20, 2020
Primary completion
Aug 2021 (estimated)
Completion
Aug 2022 (estimated)
Last update
Dec 3, 2020

Study contacts

Yi Feng, MD,PhD
Contact
yifeng65@sina.com
86-010-88325581
Yi Feng, MD,PhD
principal investigator · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion